Can Progesterone and Tranexamic Acid Be Used Together?
Yes, progesterone and tranexamic acid (TXA) can be used together safely, and there is evidence supporting their concurrent use in specific obstetric contexts, particularly for managing short cervix and preventing preterm birth. No drug interactions or contraindications exist between these medications based on current evidence.
Evidence for Concurrent Use
Obstetric Applications
Progesterone and TXA have complementary mechanisms and can be administered simultaneously without safety concerns:
In patients with short cervix receiving vaginal progesterone who subsequently require cerclage placement, continuation of vaginal progesterone post-operatively is associated with significantly reduced rates of spontaneous preterm birth at <34 weeks (2.2% vs 18.4%; adjusted OR 0.10) and at <37 weeks (9.1% vs 29.7%; adjusted OR 0.24) 1
Patients treated with both vaginal progesterone and cerclage for progressive cervical shortening demonstrated increased latency to delivery (17.0 vs 13.1 weeks) compared to those without progesterone 1
The hazard ratio for early delivery was reduced after cerclage in patients treated concomitantly with vaginal progesterone (adjusted HR 0.49,95% CI 0.27-0.87), with improvements in neonatal outcomes including NICU admission, respiratory distress syndrome, and necrotizing enterocolitis 1
No Drug Interaction Concerns
The FDA labeling for TXA explicitly states that no formal drug interaction studies have been conducted, and there are no listed interactions with progesterone:
TXA's primary concern is avoiding concomitant use with pro-thrombotic agents such as Factor IX concentrates, anti-inhibitor coagulant concentrates, and hormonal contraceptives 2
Progesterone used for pregnancy maintenance (vaginal or intramuscular) is distinct from combined hormonal contraceptives and does not carry the same thrombotic risk profile 2
Clinical Context Considerations
When using these medications together, consider the specific clinical indication:
For short cervix/preterm birth prevention: Vaginal progesterone (typically 200 mg daily) is the standard treatment, and TXA would only be added if postpartum hemorrhage occurs 1
For postpartum hemorrhage: TXA should be administered within 3 hours of birth (1 g IV over 10 minutes, with potential second dose) regardless of whether the patient was receiving progesterone during pregnancy 1
For abnormal uterine bleeding: Both TXA and progestins (including medroxyprogesterone acetate) are effective treatments that can be used sequentially or in different clinical scenarios, though they are typically not administered simultaneously for this indication 3, 4, 5, 6
Important Safety Considerations
Monitor for TXA-specific contraindications regardless of progesterone use:
Avoid TXA in patients with active intravascular clotting, subarachnoid hemorrhage, or known thromboembolic events during pregnancy 2
TXA carries risks of seizures (particularly at high doses or with neuraxial administration), hypersensitivity reactions, and visual disturbances 2
The 3-hour window for TXA administration after birth or trauma is critical—administration beyond this timeframe may be harmful 1, 7
Progesterone continuation does not alter TXA safety profile: